-Reuters
HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $49
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $47 to $49.
Related Posts
Trump-Related Digital World Acquisition, Netflix, Alibaba, Nuvve Holding, Tesla: Why These 5 Stocks Are On Investors’ Radars Today
Major U.S. indices were mixed on Tuesday with the Dow Jones Industrial Average down 0.25% at 37,905.45 at the end of trading.
Can Bitcoin Repeat History? Crypto Enthusiasts Optimistic For A Santa Claus Rally This Holiday Season
As the final month of the year approaches, crypto-enthusiasts are buzzing with anticipation of a potential ‘Bitcoin Santa Claus rally’, reminiscent of the price boosts witnessed in 2013 and 2017.
Samsung Eyes ChatGPT-Like Capabilities For Smartphones: Report
Samsung Electronics Co, Ltd (OTC:SSNLF) developed customized next-generation memory chips for large-size AI applications, like ChatGPT, that gained wide attention,…